论文部分内容阅读
非小细胞肺癌 (ＮＳＣＬＣ)由于起病隐匿 ,临床上发现时多为晚期 ,临床治疗上多以内科化疗为主。但疗效并不尽人意。异环磷酰胺 (ＩＦＯ)及其尿路保护剂美司钠的出现为ＮＳＣＬＣ的治疗提供了希望。在国外以ＩＦＯ为主的方案治疗有效率在 40 %— 5 0 %之间。 1 995年 1月— 1 9
Since non-small cell lung cancer (NSCLC) is often found to be occult and clinically found to be of late stage, clinical treatment is mainly based on internal chemotherapy. However, the efficacy is not satisfactory. The emergence of ifosfamide (IFO) and its urinary tract protector Mesna has provided hope for the treatment of NSCLC. The treatment efficiency of IFO-based regimens abroad is between 40% and 50%. January 995 - January 9